Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
3/2014 not set
BioMAS
BioMAS Overview
BioMAS Ltd is a clinical-stage company focusing on the invention, development, and commercialization of tellurium-based compounds. The companys lead molecules, AS101 and SAS, are small tellurium-based compounds developed for the treatment of various conditions. The molecules have integrin-inhibitory properties. Integrins are emerging therapeutic targets in many human pathologies.
The companys AS101/SAS drugs have demonstrated preclinical and clinical safety and efficacy for autoimmune-inflammatory diseases (psoriasis, arthritis, Crohns, and MS), certain viral conditions (HPV warts), angiogenesis-related diseases (AMD), thrombocytopenia, neutropenia, and fertility preservation following chemotherapy and radiotherapy.
A 15.4% stake in the company was acquired by Cosmo Pharmaceuticals (XSWS:COPN) for ILS 7 million on March 27, 2014.